Clinical Assessment of Potential Cardiac Risk for Your Drug

The thorough and precise evaluation of cardiac effects is a critical element of new chemical entity development. You can choose to add early cardiac safety assessment to your first-in-human studies, or wait and perform a Thorough QT prolongation study; either way, we can help you with the study design and conduct.

In this educational video, Dr. Beatrice Setnik, Altasciences’ Chief Scientific Officer, walks you through the differences between early and late QT prolongation testing.

Watch the video.

Speak with our experts today for help in deciding between early and late QT prolongation testing.  

You may also be interested in the following: 

• Webpage: QT Assessment
• Fact Sheets:
  • Safety Pharmacology
  • Cardiac Assessment 
  • First-in-Human
• The Altascientist: Cardiac Clinical Trials, Global Regulatory Requirements, Design, and Timing of QT Assessment (Case Study Included)

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept.